The effectiveness of chemoprophylaxis against malaria for non-immune migrant workers in eastern Thailand

1981 CDC, 1985, Adverse reactions to Fansidar and updated recommendations for its use in the prevention of malaria, Morbidity and Mortality Weekly Report, 33, 713 Colton, 1974 Cook, 1986, Serious problems with antimalarial drugs, Journal of Infectious Diseases, 13, 1 FDA, 1985, Boxed warning added to Fansidar labeling, FDA Drug Bulletin, 15, 21 Hall, 1976, The treatment of malaria, British Medical Journal, i, 323, 10.1136/bmj.1.6005.323 Haynes, 1979, Determinations of compliance: the disease and the mechanics of treatment, 49 Hurwitz, 1981, Resistance of Plasmodium falciparum malaria to sulfadoxine-pyrimethamine (Fansidar) in a refugee camp in Thailand, Lancet, i, 1068, 10.1016/S0140-6736(81)92239-X Kamolratanakul, 1984, Chemoprophylaxis against malaria in eastern Thailand, Chulalongkorn Medical Journal, 28, 1311 Miller, 1986, Severe cutaneous reactions among American travellers using pyrimethamine-sulfadoxine (Fansidar®) for malaria prophylaxis, American Journal of Tropical Medicine and Hygiene, 35, 451, 10.4269/ajtmh.1986.35.451 Salako, 1984, Toxicity and side-effects of antimalarials in Africa: a critical review, Bulletin of the World Health Organization, 62, 63 WHO, 1974, Sixteenth Report of the WHO Expert Committee on Malaria, 1 WHO, 1986, Antimalarial drug risk, Bulletin of the World Health Organization, 64, 504 WHO, 1988, Precautions against certain diseases and injuries, 46